DEMSER Access Program

Providing financial support* and home delivery of your DEMSER

Our DEMSER Access Program team is here to help.
Call us Monday-Friday, 8:00 AM – 8:00 PM ET: 1 (888) 607-7267

$25 Monthly Co-pays*

The DEMSER Access Program offers financial support: patients who have coverage for DEMSER through their commercial insurance may be eligible* to receive the prescribed product for as little as a $25 monthly co-pay. Patients without commercial insurance may be eligible for alternative financial assistance.

Home Delivery

Your medication can be mailed directly to your home through a specialty pharmacy, which offers access to pharmacists, auto-fill prescriptions, and direct follow-up with physicians.

Get Started

Enroll by downloading and printing the Demser Access Program Enrollment Form.
Complete the form and send it to:

DEMSER Access Program
PO BOX 220667
Charlotte, NC 28222-0667
FAX: (855) 735-4624

If you have questions about the program or enrollment process, please call
1-888-607-7267 Monday through Friday 8:00 AM – 8:00 PM ET for more information.


DEMSER® (metyrosine) capsules are indicated in the treatment of patients with pheochromocytoma for: preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and/or chronic treatment of patients with malignant pheochromocytoma. DEMSER is not recommended for the control of essential hypertension.


  • DEMSER is contraindicated in persons known to be hypersensitive to this compound.
  • Maintain adequate intravascular volume intraoperatively (especially after tumor removal) and postoperatively to avoid hypotension and decreased perfusion of vital organs resulting from vasodilatation and expanded volume capacity.
  • Life-threatening arrhythmias may occur during anesthesia and surgery. Monitor blood pressure and electrocardiogram continuously during surgery.
  • DEMSER does not eliminate the danger of hypertensive crises or arrhythmias during manipulation of the tumor, and the alpha-adrenergic blocking drug, phentolamine, may be needed.
  • DEMSER may add to the sedative effects of alcohol and other CNS depressants, e.g., hypnotics, sedatives, and tranquilizers.
  • To minimize the risk of crystalluria, patients should be urged to maintain water intake sufficient to achieve a daily urine volume of 2000 mL or more, particularly when doses greater than 2 g per day are given. Routine examination of the urine should be carried out. If metyrosine crystalluria occurs, fluid intake should be increased further. If crystalluria persists, the dosage should be reduced or the drug discontinued.
  • Observe caution in patients with impaired hepatic or renal function.
  • Warn patients about engaging in activities requiring mental alertness and motor coordination, such as driving a motor vehicle or operating machinery.
  • Advise patients to maintain liberal fluid intake.
  • Use caution in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
  • The most common adverse reaction to DEMSER is moderate to severe sedation. Other commonly reported adverse reactions are extrapyramidal signs such as drooling, speech difficulty and tremor in approximately 10 percent of patients, occasionally accompanied by trismus and frank Parkinsonism. Anxiety and psychic disturbances such as depression, hallucinations, disorientation, and confusion may occur. Diarrhea occurs in about 10 percent of patients and may be severe.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health Customer Service at 1-800-321-4576 or FDA at 1-800-FDA-1088 or